Cisplatin

checkpoint kinase 1 ; Homo sapiens







65 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35220216 Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. 2022 Mar 1
2 33472956 Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. 2021 Jan 20 2
3 33536335 SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. 2021 Feb 9 1
4 33987368 Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair. 2021 Apr 3
5 34134962 [Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting ovarian cancer cells]. 2021 May 20 1
6 34474677 CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer. 2021 Sep 3 1
7 34719665 Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer. 2021 Nov 1 1
8 31782150 Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. 2020 Aug 15 1
9 32371584 CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma. 2020 Jun 1
10 32610557 Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts. 2020 Jun 29 1
11 33216839 Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11-Rad50-Nbs1 complex in the repair of cisplatin-induced DNA cross-links. 2020 Nov 3 1
12 33261142 Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. 2020 Nov 27 2
13 30665195 Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21. 2019 Feb 22 1
14 30771522 Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. 2019 Jun 7
15 31061066 Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin. 2019 Jul 1 6
16 31078449 FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer. 2019 Jun 2
17 31140586 Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer. 2019 Jul 2
18 31441116 Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin. 2019 Nov 1
19 31528122 Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. 2019 1
20 31839711 VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response. 2019 5
21 29704517 DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. 2018 Aug 1 4
22 29890208 The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. 2018 Sep 28 1
23 30145203 Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. 2018 Nov 28 1
24 30260263 RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway. 2018 2
25 28262781 WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. 2017 Mar 6 2
26 28291626 Mus81 knockdown sensitizes colon cancer cells to chemotherapeutic drugs by activating CHK1 pathway. 2017 Oct 3
27 28454371 Synergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathway. 2017 Apr 1
28 28490518 CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. 2017 Jul 15 1
29 28888100 Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells. 2017 Oct 1
30 26657501 ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. 2016 Jan 12 4
31 27163202 Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest. 2016 Jun 7
32 27191498 Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. 2016 Jul 5 1
33 27246979 Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. 2016 Jun 28 2
34 27664008 Dietary flavonoid derivatives enhance chemotherapeutic effect by inhibiting the DNA damage response pathway. 2016 Nov 15 1
35 25593194 Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. 2015 Jan 20 2
36 25774168 Targeting lung cancer through inhibition of checkpoint kinases. 2015 1
37 26161259 Triptolide potentiates lung cancer cells to cisplatin-induced apoptosis by selectively inhibiting the NER activity. 2015 1
38 26313152 IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. 2015 Sep 29 1
39 24218165 Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells. 2014 Jan 1
40 24362713 Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. 2014 Jan 1
41 24853623 Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation. 2014 May 1
42 23275151 PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. 2013 Apr 1
43 23548269 ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. 2013 Jun 15 1
44 23839309 Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. 2013 Sep 1
45 21927021 The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. 2012 Apr 26 5
46 22537224 Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. 2012 Apr 26 4
47 22585575 CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. 2012 Jun 2
48 22743332 BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. 2012 Nov 1
49 22942255 Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. 2012 Nov 15 3
50 22957056 Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. 2012 1